Management of Autoimmune Hepatitis Flare
Start predniso(lo)ne at 0.5 mg/kg/day (up to 40 mg/day maximum) immediately, combined with a steroid-sparing agent—either mycophenolate mofetil (1,000 mg/day initially, increasing to 1,500-2,000 mg/day at week 2) or azathioprine (50 mg/day initially, increasing to 1-2 mg/kg/day at week 4). 1
Initial Assessment and Risk Stratification
When managing an AIH flare, immediately determine disease severity:
Acute severe AIH without liver failure (jaundice, INR 1.5-2.0, no encephalopathy): Initiate corticosteroids as above. If no improvement within 3-7 days, refer urgently to a transplant center 1
Acute severe AIH with ALF or ACLF (INR >2, hepatic encephalopathy): Discuss immediately with a transplant center for direct evaluation. Corticosteroid response rates are only 8-41% in this population. If steroids are given, monitor closely for infections 1
Predictors of steroid failure: MELD score >27 (83.3% sensitivity, 78.9% specificity), presence of hepatic encephalopathy, and fibrosis grade ≥F3 indicate poor response to corticosteroids and should trigger early transplant evaluation 2
Corticosteroid Selection and Dosing
Prednisolone is the standard first-line corticosteroid. The initial dose should not exceed 40 mg/day or 0.5 mg/kg/day, given as a single morning dose 3. Higher doses (1 mg/kg/day) increase adverse effects without improving response rates 3.
Budesonide (9 mg/day) is an alternative in non-cirrhotic patients without liver failure, offering lower cosmetic side effects. However, it should never be used in cirrhosis due to intrahepatic shunting that reduces efficacy and increases systemic exposure 3.
Intravenous methylprednisolone can be used in acute severe AIH, though caution is warranted—hepatotoxicity occurs in 6-8% of patients receiving this agent for other conditions, with 2% being severe or fatal 3. Intravenous hydrocortisone is safer when oral absorption is compromised 3.
Steroid-Sparing Agent Selection
Combination therapy with a steroid-sparing agent is mandatory except in specific circumstances (see below). Non-use of steroid-sparing agents is independently associated with higher death/transplant rates 3.
First-line options:
- Mycophenolate mofetil: Start 1,000 mg/day with corticosteroids, increase to 1,500-2,000 mg/day at week 2. MMF-related toxicity is rare, making it attractive for rapid escalation 1
- Azathioprine: Start 50 mg/day 2 weeks after corticosteroids, increase to 1-2 mg/kg/day at week 4. Monitor closely during first 6 weeks when toxicity most commonly occurs 1
Steroid monotherapy is acceptable only in:
- Decompensated cirrhosis (many centers avoid adding steroid-sparing agents)
- Uncertain AIH diagnosis (steroid response helps confirm diagnosis)
- Expected short treatment duration
- TPMT deficiency or concurrent allopurinol therapy
- Current or recent cancer 3
Monitoring Protocol
Week 2: Check safety biomarkers, particularly in azathioprine-treated patients (toxicity peaks in first 6 weeks) 1
Week 4: Obtain ALT and IgG to assess early response, especially in MMF-treated patients 1
Weeks 12 and 24: Measure ALT and IgG to determine biochemical response 1
After achieving complete biochemical response (normal ALT and IgG): Follow-up every 3-6 months to confirm sustained remission 1
Corticosteroid Tapering
Taper prednisolone over 3 months in 5-10 mg decrements every 2 weeks if transaminases fall gradually (as occurs in 90% of cases) 3. Individualize tapering based on biochemical response, complications, and fibrosis stage 1.
Supportive Measures
- Calcium and vitamin D supplementation for all patients on long-term corticosteroids 1
- Thyroid function monitoring every 6-12 months (thyroid disorders can develop during follow-up) 1
- Transient elastography regularly to monitor fibrosis progression 1
Special Considerations
Pregnancy: Maintain adequate immunosuppression—complete biochemical response at conception and during pregnancy reduces flare and prematurity rates. Prednisolone and azathioprine are safe; mycophenolate is absolutely contraindicated (teratogenic) and must be stopped at least 3 months before conception 1
Refractory disease (15% of patients): Second-line options include mycophenolate mofetil, tacrolimus, or cyclosporine. Third-line options include rituximab (appears safe and effective in reducing transaminases, IgG, and steroid requirements) 4, 5, 6 or infliximab 7.
Critical Pitfall
Do not delay treatment while awaiting liver biopsy results if clinical and biochemical features strongly suggest AIH flare. However, in drug-induced autoimmune-like hepatitis, perform biopsy if there is no prompt resolution after stopping the suspected drug 3. The key distinction: true AIH flares require immediate immunosuppression, while drug-induced cases may resolve with drug withdrawal alone.